Breast Cancer: Basic and Clinical Research

Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer

Submit a Paper

Breast Cancer: Basic and Clinical Research 2015:9 3-8

Original Research

Published on 09 Apr 2015

DOI: 10.4137/BCBCR.S23156

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Breast Cancer: Basic and Clinical Research


Background: To evaluate sirtuin-7 (SirT7) mRNA expression status in breast cancer patients with different metastatic stages and survey SirT7 mRNA expression status in eight different types of cancer.

Methods: The expression of SirT7 in the commercially available TissueScan qPCR Breast Cancer Disease cDNA arrays containing 16 normal, 23 Stage I, 36 IIA, 22 IIB, 8 IIIA, 23 IIIA, 6 IIIB, 13 IIIC, and 5 IV were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) assay. Similar analysis was performed in TissueScan qPCR Cancer Survey cDNA array, which includes breast, colon, kidney, liver, lung, ovarian, prostate, and thyroid specimens.

Results: The mRNA expression levels of SirT7 were significantly higher in breast cancer samples compared to normal breast specimens (P < 0.001). Stratification of patients into groups according to metastatic stages indicated statistically significantly higher levels of SirT7 mRNA in CS-I, CS-II, and CS-III when compared to normal breast tissue (P < 0.05). Notably, SirT7 mRNA levels were higher in CS-I, CS-IIA, CS-IIB, and CS-IIIA (P < 0.05). Additionally, there were significantly lower SirT7 mRNA levels in thyroid carcinoma when compared to their corresponding normal tissue (P < 0.05).

Conclusions: Our results indicate an increase in the mRNA expression level of SirT7 in breast cancer, particularly in CS-I, CS-IIA, CS-IIB, and CS-IIIA. The relationship of altered SirT7 with breast cancer progression and patient survival should be prospectively explored in future studies.




BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
The submission process for manuscript publication in Breast Cancer: Basic and Clinical Research is as easy as A,B,C!  Any minor hiccups I encountered were quickly addressed by Libertas' expert staff via prompt emails, and the timelines between initial submission and publication are surely the shortest on record!  I will definitely be submitting future manuscripts to this journal, and look forward to working with their professional and expert team.
Dr Maggie Laidlaw (Nutrasource Diagnostics Inc, Guelph, Ontario, Canada)
More Testimonials

Quick Links

New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube